MetaCap

Autolus Therapeutics plc ADR (AUTL)

NASDAQ: AUTLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9073-0.0723 (-7.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AUTL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$241.65M
EPS (TTM)
-$0.96
52-week range
0.896 – 2.58
Day range
0.8963 – 0.9797
Volume / Avg
3.90M / 2.07M
Beta
—

52-week range

$0.896$2.58

AUTL stock today

Autolus Therapeutics (AUTL) closed at $0.9073 on Nov 20, down 7.38% (-$0.0723), versus the S&P 500's 3.70% decline. At this level, AUTL sits near the bottom of its 52-week range of $0.896 to $2.58: 64.8% below the high, set on Aug 19, 2026 and 1.3% above the low. AUTL is down 54.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.2%.

Autolus Therapeutics has posted a net loss over the last twelve months (EPS of -$0.96), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Autolus Therapeutics

Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Christian Martin Itin Ph.D.
Headquarters
London
Employees
752
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Autolus Therapeutics generated $75.4 million in revenue, up 644.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Autolus Therapeutics reported a net loss of $287.5 million, compared with a loss of $220.7 million a year earlier. Gross margin was -27.8% (down from -12.5%) and operating margin -358.9%.

Autolus Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$75.39M$10.12M$1.70M——
Growth+644.94%+496.00%———
Net income$-287.53M$-220.66M$-208.38M$-148.84M$-142.10M
EPS (diluted)$-1.08$-0.86$-1.20$-1.57$-1.97

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$8.36+821.42%

  • Strong buy 1
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.21 vs $-0.21

AUTL news

All AUTL news

Autolus Therapeutics peers

Health Care sector
AUTL peer companies
CompanyPrice% ChgMarket capCompare
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs AUTL
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs AUTL
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs AUTL
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs AUTL
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs AUTL
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs AUTL
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs AUTL
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs AUTL

Indexes, lists and sector

Autolus Therapeutics stock FAQ

What is Autolus Therapeutics's stock price today?

AUTL last traded at $0.9073 as of Nov 20, 4:00 PM EST, down 7.38% on the day. Prices are delayed at least 15 minutes.

Who is Autolus Therapeutics's CEO?

Dr. Christian Martin Itin Ph.D. is the chief executive officer of Autolus Therapeutics plc ADR, which has about 752 employees.

What is the AUTL 52-week high?

The 52-week high for AUTL is $2.58 and the 52-week low is $0.896. The stock is currently 64.8% below its high.

Compare AUTL